At Horizons 2022, a cloudy outlook for psychedelics

Several weeks ago, I attended the Horizons: Perspectives on Psychedelics conference in New York City. The gathering attracts scientists, entrepreneurs, investors, activists, lawyers, therapists, and not a few party-goers, about 1,000 people in all; it’s a great place to take the pulse of the sector. I came away more impressed than ever by the work of the scientists who are researching the benefits of MDMA, psilocybin, and LSD, but wondering where the money will come from to get these drugs into the hands of people who need them. Click here to read my take, published on Medium.